Disclosed are a novel immunoassay format design for determining a total antibody, and a kit accordingly provided for detecting antibodies of a pathogen or pathogens of infectious diseases within a human blood sample, wherein the kit comprises: a first reagent containing at least one antigen coated on a solid phase support and an anti-human IgM antibody coated on a solid phase support; and a second reagent containing at least one labelled antigen and a labelled anti-human IgG antibody, wherein at least one antigen of the at least one antigen coated on a solid phase support and at least one antigen of the at least one labelled antigen can bind to the same IgG antibody or the same IgM antibody in the sample. The kit can overcome the disadvantages caused by detection principles while retaining the advantages of each detection principle. In addition, also provided is a new method for detecting an antibody produced after the infection of a pathogen or pathogens in a sample.

Disclosed are a novel immunoassay format design for determining a total antibody, and a kit accordingly provided for detecting antibodies of a pathogen or pathogens of infectious diseases within a human blood sample, wherein the kit comprises: a first reagent containing at least one antigen coated on a solid phase support and an anti-human IgM antibody coated on a solid phase support; and a second reagent containing at least one labelled antigen and a labelled anti-human IgG antibody, wherein at least one antigen of the at least one antigen coated on a solid phase support and at least one antigen of the at least one labelled antigen can bind to the same IgG antibody or the same IgM antibody in the sample. The kit can overcome the disadvantages caused by detection principles while retaining the advantages of each detection principle. In addition, also provided is a new method for detecting an antibody produced after the infection of a pathogen or pathogens in a sample.

Methods of determining infection type are disclosed. In one embodiment, the method comprises measuring the amount of TRAIL and/or IP10 no more than two days from symptom onset.

Methods of determining infection type are disclosed. In one embodiment, the method comprises measuring the amount of TRAIL and/or IP10 no more than two days from symptom onset.

Some embodiments described herein relate to systems and methods operable to combine immunoassay and Total Protein techniques in a single sample run. Some embodiments described herein allow for multiple sequential immunoassays to be performed in the same microfluidic device. Some embodiments described herein relate to stripping reagents operable to remove primary antibodies associated with immunoassays. Such stripping reagents can allow for additional immunoassays and/or Total Protein assays to be performed on the same sample.

Some embodiments described herein relate to systems and methods operable to combine immunoassay and Total Protein techniques in a single sample run. Some embodiments described herein allow for multiple sequential immunoassays to be performed in the same microfluidic device. Some embodiments described herein relate to stripping reagents operable to remove primary antibodies associated with immunoassays. Such stripping reagents can allow for additional immunoassays and/or Total Protein assays to be performed on the same sample.

The present disclosure relates to a microfluidic immunoassay chip and a microfluidic line immunoassay method. The microfluidic immunoassay chip includes a loading cell, a reaction and detection cell, a washing cell, an enzyme storing cell, a substrate cell, and a termination cell, and a waste liquid cell. A detection membrane strip is disposed in the reaction and detection cell and coated with a capture antigen or a capture antibody.

Disclosed is a glucose-6-phosphate dehydrogenase mutant and a use thereof in preparing a detection reagent. Compared with a wild-type glucose-6-phosphate dehydrogenase mutant, the glucose-6-phosphate dehydrogenase mutant contains a combination of the following mutations: 56C, 306C, and 454C. A detection kit prepared by using the glucose-6-phosphate dehydrogenase has strong specificity, high sensitivity, convenient operation, a short detection time, accurate quantification, and is suitable for high-throughput detection.

Disclosed is a glucose-6-phosphate dehydrogenase mutant and a use thereof in preparing a detection reagent. Compared with a wild-type glucose-6-phosphate dehydrogenase mutant, the glucose-6-phosphate dehydrogenase mutant contains a combination of the following mutations: 56C, 306C, and 454C. A detection kit prepared by using the glucose-6-phosphate dehydrogenase has strong specificity, high sensitivity, convenient operation, a short detection time, accurate quantification, and is suitable for high-throughput detection.

The present invention relates to highly modular amphiphilic polymer-dendron hybrids comprising hydrophobic dendrons conjugated to hydrophilic polymers that can be synthesized with a high degree of structural freedom, for suspending SWCNTs in aqueous solution. Utilizing the susceptibility of the polymer-dendrons towards enzymatic degradation, the present invention provides methods of detecting the presence of an enzyme in a sample as well as methods of monitoring of enzymatic activity by changes in the SWCNT fluorescent signal.